Equities analysts expect Zimmer Biomet Holdings Inc (NYSE:ZBH) to report earnings per share (EPS) of $1.87 for the current quarter, Zacks reports. Ten analysts have made estimates for Zimmer Biomet’s earnings. The lowest EPS estimate is $1.83 and the highest is $1.90. Zimmer Biomet reported earnings of $2.13 per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 12.2%. The firm is scheduled to issue its next quarterly earnings report on Thursday, April 26th.
On average, analysts expect that Zimmer Biomet will report full-year earnings of $7.82 per share for the current fiscal year, with EPS estimates ranging from $7.68 to $8.25. For the next fiscal year, analysts forecast that the company will report earnings of $8.37 per share, with EPS estimates ranging from $8.00 to $9.05. Zacks’ EPS calculations are an average based on a survey of research analysts that cover Zimmer Biomet.
Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Tuesday, January 30th. The medical equipment provider reported $2.10 EPS for the quarter, meeting the consensus estimate of $2.10. The company had revenue of $2.07 billion during the quarter, compared to the consensus estimate of $2.03 billion. Zimmer Biomet had a return on equity of 15.45% and a net margin of 23.51%. The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.14 EPS.
Several research firms have recently commented on ZBH. Goldman Sachs Group raised Zimmer Biomet from a “sell” rating to a “neutral” rating and set a $125.00 price objective for the company in a report on Tuesday, December 19th. Stifel Nicolaus raised Zimmer Biomet from a “hold” rating to a “buy” rating and increased their price objective for the company from $120.00 to $168.00 in a report on Wednesday, January 31st. Canaccord Genuity reissued a “hold” rating and issued a $132.00 price objective on shares of Zimmer Biomet in a report on Friday, January 5th. Robert W. Baird restated a “buy” rating on shares of Zimmer Biomet in a research note on Wednesday, January 31st. Finally, BMO Capital Markets restated a “buy” rating and issued a $142.00 price target on shares of Zimmer Biomet in a research note on Tuesday, December 12th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $141.67.
Zimmer Biomet (ZBH) traded up $0.06 during midday trading on Friday, hitting $118.74. The stock had a trading volume of 325,769 shares, compared to its average volume of 1,422,870. The firm has a market cap of $24,037.61, a P/E ratio of 13.26, a PEG ratio of 2.08 and a beta of 1.08. The company has a current ratio of 1.52, a quick ratio of 0.83 and a debt-to-equity ratio of 0.76. Zimmer Biomet has a 12 month low of $108.03 and a 12 month high of $133.49.
The company also recently disclosed a quarterly dividend, which was paid on Monday, January 29th. Shareholders of record on Friday, December 29th were given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.81%. The ex-dividend date was Thursday, December 28th. Zimmer Biomet’s payout ratio is 10.65%.
In other Zimmer Biomet news, VP Chad F. Phipps sold 20,826 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $115.95, for a total transaction of $2,414,774.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Bryan C. Hanson acquired 25,077 shares of the stock in a transaction on Tuesday, February 20th. The shares were purchased at an average price of $119.68 per share, for a total transaction of $3,001,215.36. The disclosure for this purchase can be found here. 1.07% of the stock is owned by company insiders.
A number of hedge funds have recently bought and sold shares of the business. KCM Investment Advisors LLC increased its position in Zimmer Biomet by 10.8% during the 4th quarter. KCM Investment Advisors LLC now owns 31,222 shares of the medical equipment provider’s stock worth $3,768,000 after buying an additional 3,053 shares during the period. Xact Kapitalforvaltning AB increased its position in Zimmer Biomet by 7.0% during the 4th quarter. Xact Kapitalforvaltning AB now owns 39,182 shares of the medical equipment provider’s stock worth $4,728,000 after buying an additional 2,567 shares during the period. CNB Bank bought a new position in Zimmer Biomet during the 4th quarter worth $566,000. We Are One Seven LLC bought a new position in Zimmer Biomet during the 4th quarter worth $137,000. Finally, APCM Wealth Management for Individuals bought a new position in Zimmer Biomet during the 4th quarter worth $231,000. Hedge funds and other institutional investors own 88.18% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Zimmer Biomet Holdings Inc (ZBH) Expected to Announce Earnings of $1.87 Per Share” was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://ledgergazette.com/2018/02/22/zimmer-biomet-holdings-inc-zbh-expected-to-announce-earnings-of-1-87-per-share.html.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.